<p><em>期权协议支持 Vector 进入 808 亿美元的肽市场，提供 22 种新型药品级配方</em></p>
<p>威斯康星州梅奎恩，2026 年 5 月 13 日/PRNewswire/ -- Vector Science &amp; Therapeutics（&#34;Vector&#34;或&#34;公司&#34;）今天宣布已签署期权协议，计划分期现金支付购买 LyoGenesis Plus 最多 15% 的股权，最高金额为 1,000,000 美元（&#34;期权&#34;）。该期权可在三年内行使。LyoGenesis Plus 已与 MPP Group LLC（&#34;MPP&#34;）达成协议，收购这家注册于 FDA、符合 cGMP 标准的合同开发和制造组织，总部位于威斯康星州梅奎恩。如果在三年内完全行使该期权，Vector 将获得 MPP 的 15% 所有权，从而为 Vector 日益增长的肽配方和药物输送产品提供长期的药品级制造平台。</p>
<p><strong>关键亮点</strong></p>
<ul>
<li><strong>FDA 注册的 cGMP 制造</strong> — MPP 在威斯康星州梅奎恩运营着一座现代化的 35,000 平方英尺设施，配备了先进的分析仪器。该期权使 Vector 通过 LyoGenesis 在这一基础设施中获得所有权，而无需建设类似设施所需的成本和时间。</li>
<li><strong>22 种新型肽配方</strong> — Vector 和 MPP 将共同开发具有高达 24 个月稳定性的常温肽配方，包括 14 种最近从 FDA 第 2 类名单中移除的肽。</li>
<li><strong>通过 LyoGenesis Plus 的资本杠杆</strong> — LyoGenesis Plus 资本充足，拥有 200 万美元的设备信用额度和 100 万美元的应收账款融资，使 Vector 在制造需求增长时能够无稀释地获得扩展资本。</li>
</ul>
<p>&#34;拥有一个 FDA 注册的 cGMP 制造设施是任何认真致力于提供药品级治疗的公司的基础，&#34;Vector Science &amp; Therapeutics 董事长、前美国卫生与公共服务部部长 Tommy Thompson 表示。&#34;该期权为 Vector 提供了一个可信赖的长期制造平台，以建立其肽产品组合并向医生提供药品级产品。&#34;</p>
<p><strong>支持行使期权的关键要素</strong></p>
<ul>
<li><strong>期权</strong> — Vector 有权以累计现金投资的方式，从其国库中收购 LyoGenesis Plus 最多 15% 的股权，最高金额为 1,000,000 美元，可在三年内的任何时间行使。该结构允许 Vector 根据业务增长逐步投资，并保持国库和现金流。</li>
<li><strong>MPP 设施</strong> — 通过在 LyoGenesis Plus 的股权，Vector 获得了位于威斯康星州梅奎恩的 MPP FDA 注册的 cGMP 合规制造设施的所有权，而无需建设等效基础设施所需的成本或时间。</li>
<li><strong>LyoGenesis Plus</strong> — LyoGenesis Plus 由 Tommy Thompson 和 Bill Jackson 创立，旨在收购和整合制药服务公司。在收购 MPP 后，LyoGenesis Plus 计划继续在北美寻找其他 CDMO，以作为其长期增长战略的一部分。</li>
</ul>
<p>&#34;控制我们的制造平台对我们在肽市场的长期成功至关重要，&#34;Vector Science &amp; Therapeutics 首席执行官 Bill Jackson 表示。&#34;LyoGenesis Plus 和 MPP 为我们提供了一个药品级的基础——而非研究级——以便在这个 808 亿美元的市场持续增长的情况下，向医生提供新型的常温肽配方。&#34; <em>(Grandview Research) (https://www.grandviewresearch.com/industry-analysis/peptide-therapeutics-market)</em></p>
<p>Vector 的董事长 Tommy Thompson 和首席执行官 Bill Jackson 是 LyoGenesis Plus 的少数股东，共同持有不到 50% 的股权。这两位个人已声明其利益冲突，并在 Vector 董事会投票批准该交易时回避。</p>
<p><strong>监管和交易所事项</strong></p>
<p>期权的授予和行使不构成根据《多边工具 61-101：保护少数股东在特殊交易中的权益》（&#34;MI 61-101&#34;）定义的&#34;关联方交易&#34;，因为 Vector 的关联方不拥有 LyoGenesis Plus 超过 50% 的股权。无论如何，即使该交易被视为关联方交易，公司也将依赖于 MI 61-101 第 5.5(a) 和 5.7(1)(a) 节中规定的估值和少数股东批准要求的豁免，因为期权的公允市场价值或行使后可发行的股份均未超过 Vector 市值的 25%。</p>
<p>期权的行使是根据 TSXV 政策 5.3 — 非现金资产的收购和处置 — 的可审查交易，因涉及非独立方。期权在获得 TSXV 的有条件批准、提交所有所需文件并满足所有成交条件之前，无法行使。</p>
<p><em>TSXV 并未以任何方式对拟议交易的优点进行评估，也未批准或否决本新闻稿的内容。</em></p>
<p><strong>药品级与研究级肽的区别</strong></p>
<p>药品级（也称为医疗级）肽是在美国食品药品监督管理局（FDA）注册的设施中，根据当前良好生产规范（cGMP）制造的。它们经过定义规格的身份、纯度、效力、无菌性和内毒素测试，旨在在医生监督下用于人类。</p>
<p>相比之下，研究级肽仅用于实验室研究。它们通常标记为&#34;仅供研究使用&#34;或&#34;不用于人类使用&#34;，不符合药品质量或无菌标准，也不受治疗应用的监管。</p>
<p>根据该协议，Vector 和 MPP 将共同开发和制造专用于医生监督下治疗使用的药品级肽。</p>
<p><strong>关于 Vector Science &amp; Therapeutics</strong></p>
<p>Vector Science &amp; Therapeutics, Inc. 总部位于威斯康星州梅奎恩，开发新型生物机械设备和主动局部药物输送平台，以便为临床医生提供在精确性至关重要且系统性风险不可接受的情况下进行的定点干预。该公司的股票在多伦多创业交易所上市，股票代码为 PAIN。欲了解更多信息，请访问 www.vectorscience.co。</p>
<p><strong>关于 MPP Group LLC</strong></p>
<p>MPP Group LLC 是一家合同开发和制造组织，总部位于威斯康星州梅奎恩，运营着一家注册于 FDA 的药品制造设施，具备符合 cGMP 的无菌能力。MPP 为客户提供药物配方开发、分析方法开发以及小规模至中规模的无菌制造服务。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含适用的加拿大证券法意义上的前瞻性信息，包括关于肽配方的开发和制造、配方和制造活动的开始及时间、资本支出预期、市场规模以及公司的商业化战略的声明。前瞻性声明涉及已知和未知的风险、不确定性以及其他可能导致实际结果、表现或成就与所表达或暗示的结果存在重大差异的因素。Vector Science &amp; Therapeutics 不承担更新这些声明的义务，除非法律要求。</p>
<p><em>无论是多伦多创业交易所还是其监管服务提供者（根据多伦多创业交易所政策中的定义）均不对本发布的充分性或准确性承担责任。</em></p>
<p>来源：Vector Sciences &amp; Therapeutics</p>

VTVT

TVTX

RTSL

<p>Vector Science & Therapeutics 已签署一项选择权协议，计划投资高达 100 万美元以获得 LyoGenesis Plus 15% 的股权，该公司正在收购 MPP Group LLC，这是一家注册于 FDA 的 cGMP 制造组织。该协议使 Vector 能够在不承担建设设施成本的情况下，确保其肽制剂的长期制造平台。此次合作旨在开发 22 种新型药品级肽制剂，利用 MPP 的能力来满足不断增长的 808 亿美元肽市场</p>

<p><em>Option agreement Supports Vector's Entry into the $80.8 Billion Peptide Market with 22 Novel Pharmaceutical-Grade Formulations</em></p>
<div class="lb-trans"><p><em>期权协议支持 Vector 进入 808 亿美元的肽市场，提供 22 种新型药品级配方</em></p>
</div><p>MEQUON, Wis., May 13, 2026 /PRNewswire/ -- Vector Science &amp; Therapeutics () (&#34;Vector&#34; or the &#34;Company&#34;) today announced it has entered into an option agreement to purchase up to a 15% equity interest in LyoGenesis Plus for cash payments over time, from treasury for of up to US$1,000,000 (the &#34;Option&#34;). The option is exercisable over a three-year period. LyoGenesis Plus has entered into an agreement to acquire MPP Group LLC (&#34;MPP&#34;), an FDA-registered, cGMP-compliant contract development and manufacturing organization headquartered in Mequon, Wisconsin. If exercised in its entirety over the three years, the Option would give Vector a 15% ownership interest in MPP, securing a long-term pharmaceutical-grade manufacturing platform for Vector's growing portfolio of peptide formulations and drug delivery products.</p>
<div class="lb-trans"><p>威斯康星州梅奎恩，2026 年 5 月 13 日/PRNewswire/ -- Vector Science &amp; Therapeutics（&#34;Vector&#34;或&#34;公司&#34;）今天宣布已签署期权协议，计划分期现金支付购买 LyoGenesis Plus 最多 15% 的股权，最高金额为 1,000,000 美元（&#34;期权&#34;）。该期权可在三年内行使。LyoGenesis Plus 已与 MPP Group LLC（&#34;MPP&#34;）达成协议，收购这家注册于 FDA、符合 cGMP 标准的合同开发和制造组织，总部位于威斯康星州梅奎恩。如果在三年内完全行使该期权，Vector 将获得 MPP 的 15% 所有权，从而为 Vector 日益增长的肽配方和药物输送产品提供长期的药品级制造平台。</p>
</div><p><strong>Key Highlights</strong></p>
<div class="lb-trans"><p><strong>关键亮点</strong></p>
</div><ul>
<li><strong>FDA-Registered, cGMP Manufacturing</strong> — MPP operates a modern 35,000 sq. ft. facility in Mequon, Wisconsin, equipped with sophisticated analytical instrumentation. The Option gives Vector an ownership stake through LyoGenesis in this infrastructure without the cost or time required to build a comparable facility.</li>
<li><strong>22 Novel Peptide Formulations</strong> — Vector and MPP will jointly develop shelf-stable peptide formulations with a target stability of up to 24 months, including 14 peptides recently removed from the FDA Category 2 list.</li>
<li><strong>Capital Leverage Through LyoGenesis Plus</strong> — LyoGenesis Plus is well-capitalized with a $2 million equipment line of credit and a $1 million accounts receivable facility, giving Vector non-dilutive access to expansion capital as manufacturing needs grow.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>FDA 注册的 cGMP 制造</strong> — MPP 在威斯康星州梅奎恩运营着一座现代化的 35,000 平方英尺设施，配备了先进的分析仪器。该期权使 Vector 通过 LyoGenesis 在这一基础设施中获得所有权，而无需建设类似设施所需的成本和时间。</li>
<li><strong>22 种新型肽配方</strong> — Vector 和 MPP 将共同开发具有高达 24 个月稳定性的常温肽配方，包括 14 种最近从 FDA 第 2 类名单中移除的肽。</li>
<li><strong>通过 LyoGenesis Plus 的资本杠杆</strong> — LyoGenesis Plus 资本充足，拥有 200 万美元的设备信用额度和 100 万美元的应收账款融资，使 Vector 在制造需求增长时能够无稀释地获得扩展资本。</li>
</ul>
</div><p>&#34;Ownership of an FDA-registered, cGMP manufacturing facility is foundational for any company serious about delivering pharmaceutical-grade therapeutics,&#34; said Tommy Thompson, Chairman of Vector Science &amp; Therapeutics and former U.S. Secretary of Health and Human Services. &#34;This Option gives Vector a credible, long-term manufacturing platform from which to build its peptide portfolio and deliver pharmaceutical-grade products to physicians.&#34;</p>
<div class="lb-trans"><p>&#34;拥有一个 FDA 注册的 cGMP 制造设施是任何认真致力于提供药品级治疗的公司的基础，&#34;Vector Science &amp; Therapeutics 董事长、前美国卫生与公共服务部部长 Tommy Thompson 表示。&#34;该期权为 Vector 提供了一个可信赖的长期制造平台，以建立其肽产品组合并向医生提供药品级产品。&#34;</p>
</div><p><strong>Key Elements Supporting Exercise of the Option</strong></p>
<div class="lb-trans"><p><strong>支持行使期权的关键要素</strong></p>
</div><ul>
<li><strong>The Option</strong> — Vector has the right to acquire up to a 15% equity interest in LyoGenesis Plus for a cumulative cash investment, from its treasury, of up to US$1,000,000, exercisable at any time over a three-year period. This structure allows Vector to invest incrementally in line with its business growth and preserve treasury and cashflow.</li>
<li><strong>MPP Facility</strong> — Through its equity position in LyoGenesis Plus, Vector gains an ownership stake in MPP's FDA-registered, cGMP-compliant manufacturing facility in Mequon, Wisconsin, without the cost or timeline required to build equivalent infrastructure.</li>
<li><strong>LyoGenesis Plus</strong> — LyoGenesis Plus was founded by Tommy Thompson and Bill Jackson to acquire and consolidate pharmaceutical services companies. Following its acquisition of MPP, LyoGenesis Plus intends to continue seeking additional CDMOs across North America as part of its long-term growth strategy.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>期权</strong> — Vector 有权以累计现金投资的方式，从其国库中收购 LyoGenesis Plus 最多 15% 的股权，最高金额为 1,000,000 美元，可在三年内的任何时间行使。该结构允许 Vector 根据业务增长逐步投资，并保持国库和现金流。</li>
<li><strong>MPP 设施</strong> — 通过在 LyoGenesis Plus 的股权，Vector 获得了位于威斯康星州梅奎恩的 MPP FDA 注册的 cGMP 合规制造设施的所有权，而无需建设等效基础设施所需的成本或时间。</li>
<li><strong>LyoGenesis Plus</strong> — LyoGenesis Plus 由 Tommy Thompson 和 Bill Jackson 创立，旨在收购和整合制药服务公司。在收购 MPP 后，LyoGenesis Plus 计划继续在北美寻找其他 CDMO，以作为其长期增长战略的一部分。</li>
</ul>
</div><p>&#34;Controlling our manufacturing platform is critical to our long-term success in the peptide market,&#34; said Bill Jackson, Chief Executive Officer of Vector Science &amp; Therapeutics. &#34;LyoGenesis Plus and MPP give us a pharmaceutical-grade foundation — not research-grade — from which to supply physicians with novel, shelf-stable peptide formulations as that $80.8 Billion market continues to grow.&#34; <em>(Grandview Research) (https://www.grandviewresearch.com/industry-analysis/peptide-therapeutics-market)</em></p>
<div class="lb-trans"><p>&#34;控制我们的制造平台对我们在肽市场的长期成功至关重要，&#34;Vector Science &amp; Therapeutics 首席执行官 Bill Jackson 表示。&#34;LyoGenesis Plus 和 MPP 为我们提供了一个药品级的基础——而非研究级——以便在这个 808 亿美元的市场持续增长的情况下，向医生提供新型的常温肽配方。&#34; <em>(Grandview Research) (https://www.grandviewresearch.com/industry-analysis/peptide-therapeutics-market)</em></p>
</div><p>Tommy Thompson, Chairman of Vector, and Bill Jackson, Chief Executive Officer of Vector, are minority owners in LyoGenesis Plus, together holding less than 50% of its equity. Both individuals declared their conflicts of interest and recused themselves from the Vector board vote approving this transaction.</p>
<div class="lb-trans"><p>Vector 的董事长 Tommy Thompson 和首席执行官 Bill Jackson 是 LyoGenesis Plus 的少数股东，共同持有不到 50% 的股权。这两位个人已声明其利益冲突，并在 Vector 董事会投票批准该交易时回避。</p>
</div><p><strong>Regulatory and Exchange Matters</strong></p>
<div class="lb-trans"><p><strong>监管和交易所事项</strong></p>
</div><p>The grant and exercise of the Option does not constitute a &#34;related party transaction&#34; as defined under Multilateral Instrument 61-101: Protection of Minority Securityholders in Special Transactions (&#34;MI 61-101&#34;), as related parties of Vector do not own more than 50% of the equity securities of LyoGenesis Plus. In any event, even if the transaction were considered a related party transaction, the Company would rely on the exemptions from the valuation and minority shareholder approval requirements set out in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of the Option nor the shares issuable upon its exercise exceeds 25% of Vector's market capitalization.</p>
<div class="lb-trans"><p>期权的授予和行使不构成根据《多边工具 61-101：保护少数股东在特殊交易中的权益》（&#34;MI 61-101&#34;）定义的&#34;关联方交易&#34;，因为 Vector 的关联方不拥有 LyoGenesis Plus 超过 50% 的股权。无论如何，即使该交易被视为关联方交易，公司也将依赖于 MI 61-101 第 5.5(a) 和 5.7(1)(a) 节中规定的估值和少数股东批准要求的豁免，因为期权的公允市场价值或行使后可发行的股份均未超过 Vector 市值的 25%。</p>
</div><p>The exercise of the Option is a Reviewable Transaction under TSXV Policy 5.3 — Acquisitions and Dispositions of Non-Cash Assets — due to the involvement of Non-Arm's Length Parties. The Option cannot be exercised until TSXV conditional approval has been received, all required documentation has been submitted, and all closing conditions have been satisfied.</p>
<div class="lb-trans"><p>期权的行使是根据 TSXV 政策 5.3 — 非现金资产的收购和处置 — 的可审查交易，因涉及非独立方。期权在获得 TSXV 的有条件批准、提交所有所需文件并满足所有成交条件之前，无法行使。</p>
</div><p><em>The TSXV has in no way passed upon the merits of the proposed Transaction and has neither approved nor disapproved the contents of this news release.</em></p>
<div class="lb-trans"><p><em>TSXV 并未以任何方式对拟议交易的优点进行评估，也未批准或否决本新闻稿的内容。</em></p>
</div><p><strong>Pharmaceutical-Grade vs. Research-Grade Peptides</strong></p>
<div class="lb-trans"><p><strong>药品级与研究级肽的区别</strong></p>
</div><p>Pharmaceutical-grade (also called medical-grade) peptides are manufactured under the U.S. Food and Drug Administration's current Good Manufacturing Practices (cGMP) in FDA-registered facilities. They are tested to defined specifications for identity, purity, potency, sterility, and endotoxins, and they are intended for use in humans under physician supervision.</p>
<div class="lb-trans"><p>药品级（也称为医疗级）肽是在美国食品药品监督管理局（FDA）注册的设施中，根据当前良好生产规范（cGMP）制造的。它们经过定义规格的身份、纯度、效力、无菌性和内毒素测试，旨在在医生监督下用于人类。</p>
</div><p>Research-grade peptides, by contrast, are produced for laboratory study only. They are typically labeled &#34;for research use only&#34; or &#34;not for human use,&#34; are not manufactured to pharmaceutical quality or sterility standards and are not regulated for therapeutic application.</p>
<div class="lb-trans"><p>相比之下，研究级肽仅用于实验室研究。它们通常标记为&#34;仅供研究使用&#34;或&#34;不用于人类使用&#34;，不符合药品质量或无菌标准，也不受治疗应用的监管。</p>
</div><p>Under this agreement, Vector and MPP will jointly develop and manufacture pharmaceutical-grade peptides intended exclusively for physician-supervised therapeutic use.</p>
<div class="lb-trans"><p>根据该协议，Vector 和 MPP 将共同开发和制造专用于医生监督下治疗使用的药品级肽。</p>
</div><p><strong>About Vector Science &amp; Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Vector Science &amp; Therapeutics</strong></p>
</div><p>Vector Science &amp; Therapeutics, Inc., headquartered in Mequon, Wisconsin, develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions where precision matters and systemic risks are unacceptable. The Company's shares are listed on the TSX Venture Exchange under the symbol PAIN. For more information, visit www.vectorscience.co.</p>
<div class="lb-trans"><p>Vector Science &amp; Therapeutics, Inc. 总部位于威斯康星州梅奎恩，开发新型生物机械设备和主动局部药物输送平台，以便为临床医生提供在精确性至关重要且系统性风险不可接受的情况下进行的定点干预。该公司的股票在多伦多创业交易所上市，股票代码为 PAIN。欲了解更多信息，请访问 www.vectorscience.co。</p>
</div><p><strong>About MPP Group LLC</strong></p>
<div class="lb-trans"><p><strong>关于 MPP Group LLC</strong></p>
</div><p>MPP Group LLC is a contract development and manufacturing organization headquartered in Mequon, Wisconsin, operating an FDA-registered drug manufacturing facility with cGMP-compliant aseptic capabilities. MPP serves clients across pharmaceutical formulation development, analytical method development, and small- to mid-scale aseptic manufacturing.</p>
<div class="lb-trans"><p>MPP Group LLC 是一家合同开发和制造组织，总部位于威斯康星州梅奎恩，运营着一家注册于 FDA 的药品制造设施，具备符合 cGMP 的无菌能力。MPP 为客户提供药物配方开发、分析方法开发以及小规模至中规模的无菌制造服务。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This news release contains forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the development and manufacturing of peptide formulations, the commencement and timing of formulation and manufacturing activities, capital expenditure expectations, market size, and the Company's commercialization strategy. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Vector Science &amp; Therapeutics undertakes no obligation to update these statements, except as required by applicable law.</p>
<div class="lb-trans"><p>本新闻稿包含适用的加拿大证券法意义上的前瞻性信息，包括关于肽配方的开发和制造、配方和制造活动的开始及时间、资本支出预期、市场规模以及公司的商业化战略的声明。前瞻性声明涉及已知和未知的风险、不确定性以及其他可能导致实际结果、表现或成就与所表达或暗示的结果存在重大差异的因素。Vector Science &amp; Therapeutics 不承担更新这些声明的义务，除非法律要求。</p>
</div><p><em>Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.</em></p>
<div class="lb-trans"><p><em>无论是多伦多创业交易所还是其监管服务提供者（根据多伦多创业交易所政策中的定义）均不对本发布的充分性或准确性承担责任。</em></p>
</div><p>SOURCE Vector Sciences &amp; Therapeutics</p>
<div class="lb-trans"><p>来源：Vector Sciences &amp; Therapeutics</p>
</div>

Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing

PR Newswire

vTv Therap

Travere Therapeutics

Rapid Therapeutic Science Laboratories, Inc.

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

标普生物技术 3 倍做多 - Direxion

Vector Science & Therapeutics 同意获得投资 LyoGenesis Plus 的选择权，从而确保长期获得 FDA 注册的 cGMP 生产能力